Company news

Paradigm Biopharmaceuticals Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

September 2026 Quarterly Activities Report & Appendix 4C

October 29, 2026

September 2026 Quarterly Activities Report & Appendix 4C

October 29, 2026

Convening Period Extended to 27 January 2027

October 28, 2026

Convening Period Extended to 27 January 2027

October 28, 2026

Extension of Convening Period

October 22, 2026

PPS Shows Significant Pain Benefit in Rest of World Analysis

October 15, 2026

PPS Shows Significant Pain Benefit in Rest of World Analysis

October 14, 2026

Continuation of Suspension from Quotation

September 29, 2026

Appointment of Voluntary Administrators

September 29, 2026

Board Initiates Voluntary Administration

September 29, 2026

Continuation of Voluntary Suspension

September 27, 2026

Agreement to Return US$2M to Obsidian

September 24, 2026

Phase 3 Interim Result Below Continuation Threshold

September 23, 2026

Suspension from Quotation

September 22, 2026

Appendix 4E and 2026 Annual Report

August 27, 2026

June 2026 Quarterly Activities Report & Appendix 4C

July 29, 2026

Paradigm Receives $5.75m R&D Tax Incentive Refund

July 21, 2026

Drawdown of Tranche 4 under the Convertible Note Facility

July 12, 2026

PAR Completes Enrolment in Pivotal Phase 3

June 14, 2026

Results of Share Purchase Plan

May 31, 2026

DSMB 20% Review Supports Phase 3, Moldova Activated

April 29, 2026

March 2026 Quarterly Activities Report & Appendix 4C

April 27, 2026

Upsized $14M Placement Extends Runway Post IA

April 26, 2026

Paradigm Achieves 50% Patient Dosing in Phase 3

March 30, 2026

Appendix 4D and Half Year Report

February 26, 2026

Drawdown of Tranche 3 under the Convertible Note Facility

February 18, 2026

Published Canine Study Strengthens iPPS Phase 3 Rationale

February 10, 2026

Oral OA Animal Therapy Progresses via AVet Deal

February 8, 2026

December 2025 Quarterly Activities Report & Appendix 4C

January 29, 2026

iPPS Phase 2 Biomarker Results Published in Leading Journal

January 28, 2026

Phase 3 Knee OA Trial Recruitment Update

December 22, 2025

Drawdown of Tranche 2 under the Convertible Note Facility

November 17, 2025

September 2025 Quarterly Activities Report & Appendix 4C

October 29, 2025

Phase 3 Knee OA Trial Recruiting and Dosing in AUS & US

September 30, 2025

Appendix 4E and 2025 Annual Report

August 29, 2025

June 2025 Quarterly Activities Report & Appendix 4C

July 28, 2025

Paradigm Secures US$27M to Advance Phase 3 OA Trial

June 30, 2025

Paradigm Strengthens OA Pipeline with Strategic Acquisition

June 25, 2025

PAR Receives US Ethics Approval for Phase 3

May 14, 2025

March 2025 Quarterly Activities Report & Appendix 4C

April 29, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Paradigm Secures Ethics Approval for Phase 3 Trial

February 23, 2025

Loyalty and Piggyback Options Program

January 31, 2025

PAR Selects Advanced Clinical as CRO for Phase 3

January 30, 2025

Quarterly Activities/Appendix 4C Cash Flow Report

January 30, 2025

Paradigm Receives $6.3m R&D Tax Refund

January 23, 2025

PAR Capital Raising Presentation

December 8, 2024

Successful Completion of $16M Placement for Phase 3

December 8, 2024

Trading Halt

December 4, 2024

Paradigm to Proceed with Phase 3 Knee OA Trial

November 27, 2024

Older news releases →

Decks

The 5 newest of 30 decks. Every deck is listed under its year.